CN104926947A - 用于免疫耐受性诱导和免疫诊断的fviii肽 - Google Patents

用于免疫耐受性诱导和免疫诊断的fviii肽 Download PDF

Info

Publication number
CN104926947A
CN104926947A CN201510431485.4A CN201510431485A CN104926947A CN 104926947 A CN104926947 A CN 104926947A CN 201510431485 A CN201510431485 A CN 201510431485A CN 104926947 A CN104926947 A CN 104926947A
Authority
CN
China
Prior art keywords
fviii
peptide
amino acid
seq
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510431485.4A
Other languages
English (en)
Chinese (zh)
Inventor
卡塔琳娜·诺拉·施泰尼茨
保拉·玛利亚·威廉明娜范黑尔登
比吉特·玛利亚·赖佩特
汉斯-彼得·施瓦茨
哈特穆特·埃利希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baishen Co
Baxalta GmbH
Takeda Pharmaceutical Co Ltd
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CN104926947A publication Critical patent/CN104926947A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
CN201510431485.4A 2010-10-27 2011-10-27 用于免疫耐受性诱导和免疫诊断的fviii肽 Pending CN104926947A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40740210P 2010-10-27 2010-10-27
US61/407,402 2010-10-27
US201161467894P 2011-03-25 2011-03-25
US61/467,894 2011-03-25
US201161502476P 2011-06-29 2011-06-29
US61/502,476 2011-06-29
CN201180063117.9A CN103298482B (zh) 2010-10-27 2011-10-27 用于免疫耐受性诱导和免疫诊断的fviii肽

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180063117.9A Division CN103298482B (zh) 2010-10-27 2011-10-27 用于免疫耐受性诱导和免疫诊断的fviii肽

Publications (1)

Publication Number Publication Date
CN104926947A true CN104926947A (zh) 2015-09-23

Family

ID=45349271

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510431485.4A Pending CN104926947A (zh) 2010-10-27 2011-10-27 用于免疫耐受性诱导和免疫诊断的fviii肽
CN201180063117.9A Active CN103298482B (zh) 2010-10-27 2011-10-27 用于免疫耐受性诱导和免疫诊断的fviii肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180063117.9A Active CN103298482B (zh) 2010-10-27 2011-10-27 用于免疫耐受性诱导和免疫诊断的fviii肽

Country Status (20)

Country Link
US (3) US8969524B2 (cg-RX-API-DMAC7.html)
EP (2) EP2632479B1 (cg-RX-API-DMAC7.html)
JP (2) JP6122780B2 (cg-RX-API-DMAC7.html)
KR (2) KR102222864B1 (cg-RX-API-DMAC7.html)
CN (2) CN104926947A (cg-RX-API-DMAC7.html)
AR (1) AR083586A1 (cg-RX-API-DMAC7.html)
AU (2) AU2011319747C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013010362A2 (cg-RX-API-DMAC7.html)
CA (1) CA2815239C (cg-RX-API-DMAC7.html)
DK (1) DK2632479T3 (cg-RX-API-DMAC7.html)
EA (1) EA034494B1 (cg-RX-API-DMAC7.html)
ES (2) ES2639039T3 (cg-RX-API-DMAC7.html)
HK (1) HK1215442A1 (cg-RX-API-DMAC7.html)
MX (1) MX347805B (cg-RX-API-DMAC7.html)
NZ (2) NZ609474A (cg-RX-API-DMAC7.html)
PL (2) PL3260132T3 (cg-RX-API-DMAC7.html)
PT (1) PT2632479T (cg-RX-API-DMAC7.html)
SG (2) SG10201600656WA (cg-RX-API-DMAC7.html)
TW (3) TWI580430B (cg-RX-API-DMAC7.html)
WO (1) WO2012058480A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
CN104903347B (zh) * 2012-11-12 2020-02-21 艾匹托普国际股份有限公司 肽
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
US20160038575A1 (en) * 2013-03-15 2016-02-11 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
JP6488376B2 (ja) * 2014-06-12 2019-03-20 ユニヴァーシティ オブ ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬
EP3250602A1 (en) * 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
CN109804432B (zh) 2016-04-15 2023-07-14 武田药品工业株式会社 提供药代动力学药物给药方案的方法和设备
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646564A (zh) * 2002-04-18 2005-07-27 默克专利有限公司 修饰的因子ⅷ
CN1652814A (zh) * 2002-05-06 2005-08-10 比奥马林药物公司 抗原特异性免疫耐受的诱导
WO2009095646A2 (en) * 2008-01-28 2009-08-06 Circassia Limited Peptides from factor viii

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766412B1 (en) * 2004-05-21 2009-04-01 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
US7673687B2 (en) 2007-12-05 2010-03-09 Halliburton Energy Services, Inc. Cement compositions comprising crystalline organic materials and methods of using same
DE202007017320U1 (de) 2007-12-07 2008-02-28 Dittmann, Ludwig Vorrichtung zur Raumbeduftung
US20110081362A1 (en) 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646564A (zh) * 2002-04-18 2005-07-27 默克专利有限公司 修饰的因子ⅷ
CN1652814A (zh) * 2002-05-06 2005-08-10 比奥马林药物公司 抗原特异性免疫耐受的诱导
WO2009095646A2 (en) * 2008-01-28 2009-08-06 Circassia Limited Peptides from factor viii

Also Published As

Publication number Publication date
EA034494B1 (ru) 2020-02-13
PL3260132T3 (pl) 2022-08-08
US20150203567A1 (en) 2015-07-23
TW201708251A (zh) 2017-03-01
PL2632479T3 (pl) 2017-09-29
AU2011319747C1 (en) 2016-07-14
US9512198B2 (en) 2016-12-06
AU2011319747B2 (en) 2016-01-07
EP3260132B1 (en) 2022-02-09
KR102222864B1 (ko) 2021-03-04
US20120135019A1 (en) 2012-05-31
US8969524B2 (en) 2015-03-03
CA2815239C (en) 2019-02-26
EP2632479B1 (en) 2017-06-14
JP2017095463A (ja) 2017-06-01
WO2012058480A1 (en) 2012-05-03
BR112013010362A2 (pt) 2016-08-02
TW201730205A (zh) 2017-09-01
ES2912455T3 (es) 2022-05-26
MX347805B (es) 2017-05-15
AR083586A1 (es) 2013-03-06
CN103298482A (zh) 2013-09-11
NZ609474A (en) 2015-06-26
CA2815239A1 (en) 2012-05-03
SG10201600656WA (en) 2016-02-26
AU2016202155B2 (en) 2018-02-01
JP6122780B2 (ja) 2017-04-26
HK1215442A1 (zh) 2016-08-26
JP2014505014A (ja) 2014-02-27
PT2632479T (pt) 2017-07-24
ES2639039T3 (es) 2017-10-25
MX2013004753A (es) 2013-09-13
KR102040867B1 (ko) 2019-11-07
CN103298482B (zh) 2015-08-19
KR20190126189A (ko) 2019-11-08
US20170267743A1 (en) 2017-09-21
AU2016202155A1 (en) 2016-04-28
TWI580430B (zh) 2017-05-01
EA201390617A1 (ru) 2013-10-30
KR20130128404A (ko) 2013-11-26
TW201231065A (en) 2012-08-01
NZ703514A (en) 2017-02-24
AU2011319747A1 (en) 2013-05-02
EP3260132A1 (en) 2017-12-27
EP2632479A1 (en) 2013-09-04
DK2632479T3 (en) 2017-08-07
SG189914A1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
AU2016202155B2 (en) Fviii peptides for immune tolerance induction and immunodiagnostics
JP2017516752A (ja) 単離されたドナーｍｈｃ由来ペプチド及びその使用
JP6363996B2 (ja) 免疫原性が低下した凝固因子ｖｉｉｉ
EP1482961B1 (en) Use of soluble fgl2 as an immunosuppressant
HK1246211A1 (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1246211B (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1188954A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1188954B (en) Fviii peptides for immune tolerance induction and immunodiagnostics
EA043749B1 (ru) Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики
US8263757B2 (en) Promiscuous HER-2/Neu CD4 T cell epitopes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1215442

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20211018

Address after: Illinois, USA

Applicant after: Baishen Co.

Applicant after: BAXALTA GmbH

Address before: Illinois, USA

Applicant before: BAXTER INTERNATIONAL Inc.

Applicant before: BAXTER HEALTHCARE S.A.

Effective date of registration: 20211018

Address after: No. 1, 1-1, sidingmu, Daoxiu Town, Central District, Osaka City, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Illinois, USA

Applicant before: Baishen Co.

Applicant before: BAXALTA GmbH

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20150923

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1215442

Country of ref document: HK